Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

Management team

About us

Company FAQs

Corporate Governance

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

Khan_2019_iPSC-MSC-immune-tolerance-long-term-graft-survival-mouse-tracheal-transplant.pdf

Read full article

Lung transplantation is a life-saving surgical replacement of diseased lungs in patients with end-stage respiratory malfunctions. Despite remarkable short-term recovery, long-term lung survival continues to face several major challenges, including chronic rejection and severe toxic side effects due to global immunosuppression. Stem cell-based immunotherapy has been recognized as a crucial immunoregulatory regimen in various preclinical and clinical studies. Despite initial therapeutic outcomes, conventional stem cells face key limitations. The novel Cymerus™ manufacturing facilitates production of a virtually limitless supply of consistent human induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells, which could play a key role in selective immunosuppression and graft repair during rejection.

iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants